Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott Randall Plotkin, M.D.,Ph.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
Harvard College, CambridgeB.A.06/1991Chemistry

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R13CA236402 (PLOTKIN, SCOTT R) Dec 1, 2018 - Nov 30, 2020
    NIH
    Designing clinical trials for cutaneous neurofibromas, an unmet medical need for patients with neurofibromatosis 1
    Role: Principal Investigator
  2. R01CA201130 (RAMESH, VIJAYA) Aug 10, 2016 - Jul 31, 2021
    NIH
    Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma
    Role: Principal Investigator
  3. R13TR002095 (PLOTKIN, SCOTT R) Dec 4, 2015 - Apr 14, 2018
    NIH
    Enhancing patient engagement in neurofibromatosis clinical trials
    Role: Principal Investigator
  4. R13CA203289 (PLOTKIN, SCOTT R) Dec 4, 2015 - Nov 30, 2016
    NIH
    Developing Endpoints to Facilitate Clinical Trials in Rare Diseases
    Role: Principal Investigator
  5. R13NS084619 (FISHER, MICHAEL) Jun 8, 2013 - Jun 12, 2017
    NIH
    Children's Tumor Foundation 2016 Neurofibromatosis (NF) Conference
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16(7):e0252048. PMID: 34264955.
    Citations:    Fields:    
  2. Wu L, Vasilijic S, Sun Y, Chen J, Landegger LD, Zhang Y, Zhou W, Ren J, Early S, Yin Z, Ho WW, Zhang N, Gao X, Lee GY, Datta M, Sagers JE, Brown A, Muzikansky A, Stemmer-Rachamimov A, Zhang L, Plotkin SR, Jain RK, Stankovic KM, Xu L. Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci Transl Med. 2021 07 14; 13(602). PMID: 34261799.
    Citations: 1     Fields:    Translation:HumansAnimals
  3. Ahlawat S, Ly KI, Fayad LM, Fisher MJ, Lessing AJ, Berg DJ, Salamon JM, Mautner VF, Babovic-Vuksanovic D, Dombi E, Harris G, Plotkin SR, Blakeley J. Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment. Neurology. 2021 08 17; 97(7 Suppl 1):S111-S119. PMID: 34230200.
    Citations:    Fields:    Translation:Humans
  4. Akshintala S, Khalil N, Yohay K, Muzikansky A, Allen J, Yaffe A, Gross AM, Fisher MJ, Blakeley JO, Oberlander B, Pudel M, Engelson C, Obletz J, Mitchell C, Widemann BC, Stevenson DA, Plotkin SR. Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. Neurology. 2021 08 17; 97(7 Suppl 1):S99-S110. PMID: 34230196.
    Citations:    Fields:    Translation:Humans
  5. Merker VL, Lessing AJ, Moss I, Hussey M, Oberlander B, Rose T, Thalheimer R, Wirtanen T, Wolters PL, Gross AM, Plotkin SR. Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS. Neurology. 2021 08 17; 97(7 Suppl 1):S4-S14. PMID: 34230208.
    Citations:    Fields:    Translation:Humans
  6. Gross AM, Plotkin SR, Widemann BC. [REiNS] NF Clinical Trials - REiNS Collaboration 2020 Recommendations: Looking Back and Moving Ahead. Neurology. 2021 Jul 06. PMID: 34230201.
    Citations:    Fields:    
  7. Maguiness S, Berman Y, Rubin N, Dodds M, Plotkin SR, Wong C, Moertel C. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1. Neurology. 2021 08 17; 97(7 Suppl 1):S25-S31. PMID: 34230204.
    Citations:    Fields:    Translation:Humans
  8. Thalheimer RD, Merker VL, Ly KI, Champlain A, Sawaya J, Askenazi NL, Herr HP, Da JLW, Jordan JT, Muzikansky A, Pearce EM, Sakamoto FH, Blakeley JO, Anderson RR, Plotkin SR. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S32-S41. PMID: 34230197.
    Citations:    Fields:    Translation:Humans
  9. Cannon A, Pichard DC, Wolters PL, Adsit S, Erickson G, Lessing AJ, Li P, Narmore W, Röhl C, Rosser T, Widemann BC, Blakeley JO, Plotkin SR. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S15-S24. PMID: 34230202.
    Citations:    Fields:    Translation:Humans
  10. Karajannis MA, Mauguen A, Maloku E, Xu Q, Dunbar EM, Plotkin SR, Yaffee A, Wang S, Roland JT, Sen C, Placantonakis DG, Golfinos JG, Allen JC, Vitanza NA, Chiriboga LA, Schneider RJ, Deng J, Neubert TA, Goldberg JD, Zagzag D, Giancotti FG, Blakeley JO. Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. Mol Cancer Ther. 2021 Sep; 20(9):1584-1591. PMID: 34224367.
    Citations:    Fields:    
  11. Zhang JW, Chen W, Ly KI, Zhang X, Yan F, Jordan J, Harris G, Plotkin S, Hao P, Cai W. DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI. IEEE J Biomed Health Inform. 2021 Jun 09; PP. PMID: 34106871.
    Citations:    Fields:    
  12. Kukutla P, Ahmed SG, DuBreuil DM, Abdelnabi A, Cetinbas M, Fulci G, Aldikacti B, Stemmer-Rachamimov A, Plotkin SR, Wainger B, Sadreyev RI, Brenner GJ. Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas. Ann Clin Transl Neurol. 2021 07; 8(7):1508-1514. PMID: 34053190.
    Citations:    Fields:    
  13. Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K, Huson SM, Evans DG, Plotkin SR. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021 Aug; 23(8):1506-1513. PMID: 34012067.
    Citations: 1     Fields:    
  14. Dhaenens BAE, Ferner RE, Bakker A, Nievo M, Evans DG, Wolkenstein P, Potratz C, Plotkin SR, Heimann G, Legius E, Oostenbrink R. Identifying challenges in neurofibromatosis: a modified Delphi procedure. Eur J Hum Genet. 2021 Apr 26. PMID: 33903738.
    Citations:    Fields:    
  15. Radtke HB, Klein-Tasman BP, Merker VL, Knight P, Ullrich NJ, Jordan JT, Korf B, Plotkin SR. The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet J Rare Dis. 2021 02 01; 16(1):61. PMID: 33522938.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  16. Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, Allen JC, Schorry E, Korf B, Robison NJ, Goldman S, Vinks AA, Emoto C, Fukuda T, Robinson CT, Cutter G, Edwards L, Dombi E, Ratner N, Packer R, Fisher MJ. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021 Mar 01; 39(7):797-806. PMID: 33507822.
    Citations: 1     Fields:    
  17. Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, Zhang C, Angus SP, Johnson GL, Packer RJ, Allen JC, Ullrich NJ, Goldman S, Gutmann DH, Plotkin SR, Rosser T, Robertson KA, Widemann BC, Smith AE, Bessler WK, He Y, Park SJ, Mund JA, Jiang L, Bijangi-Vishehsaraei K, Robinson CT, Cutter GR, Korf BR, Blakeley JO, Clapp DW. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat Med. 2021 01; 27(1):165-173. PMID: 33442015.
    Citations: 3     Fields:    Translation:HumansAnimalsCTClinical Trials
  18. Mansouri S, Suppiah S, Mamatjan Y, Paganini I, Liu JC, Karimi S, Patil V, Nassiri F, Singh O, Sundaravadanam Y, Rath P, Sestini R, Gensini F, Agnihotri S, Blakeley J, Ostrow K, Largaespada D, Plotkin SR, Stemmer-Rachamimov A, Ferrer MM, Pugh TJ, Aldape KD, Papi L, Zadeh G. Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathol. 2021 Jan; 141(1):117. PMID: 33112994.
    Citations:    Fields:    
  19. Rios JJ, Richards BS, Stevenson DA, Oberlander B, Viskochil D, Gross AM, Dombi E, Widemann BC, Plotkin SR, May CJ, Ullrich NJ, Goldstein RY, Jain V, Schorry EK. Are Some Randomized Clinical Trials Impossible? J Pediatr Orthop. 2021 Jan; 41(1):e90-e93. PMID: 32852366.
    Citations:    Fields:    Translation:Humans
  20. Beauchamp RL, Erdin S, Witt L, Jordan JT, Plotkin SR, Gusella JF, Ramesh V. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. J Biol Chem. 2021 Jan-Jun; 296:100157. PMID: 33273014.
    Citations:    Fields:    Translation:HumansCells
  21. Beauchamp RL, Erdin S, Witt L, Jordan JT, Plotkin SR, Gusella JF, Ramesh V. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. J Biol Chem. 2020 Dec 09; 296:100157. PMID: 33461953.
    Citations:    Fields:    
  22. Strowd RE, Plotkin SR. Familial Nervous System Tumor Syndromes. Continuum (Minneap Minn). 2020 12; 26(6):1523-1552. PMID: 33273171.
    Citations:    Fields:    
  23. Mansouri S, Suppiah S, Mamatjan Y, Paganini I, Liu JC, Karimi S, Patil V, Nassiri F, Singh O, Sundaravadanam Y, Rath P, Sestini R, Gensini F, Agnihotri S, Blakeley J, Ostrow K, Largaespada D, Plotkin SR, Stemmer-Rachamimov A, Ferrer MM, Pugh TJ, Aldape KD, Papi L, Zadeh G. Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathol. 2021 01; 141(1):101-116. PMID: 33025139.
    Citations: 1     Fields:    
  24. Merker VL, Plotkin SR, Charns MP, Meterko M, Jordan JT, Elwy AR. Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Educ Couns. 2021 04; 104(4):808-814. PMID: 33051127.
    Citations:    Fields:    Translation:Humans
  25. Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, Wong ET, Gerstner ER, Dietrich J, Plotkin SR, Norden AD, Lee EQ, Nayak L, Tanaka S, Wakimoto H, Lelic N, Koerner MV, Klofas LK, Bertalan MS, Arrillaga-Romany IC, Betensky RA, Curry WT, Borger DR, Balaj L, Kitchen RR, Chakrabortty SK, Valentino MD, Skog J, Breakefield XO, Iafrate AJ, Batchelor TT. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4. PMID: 32923886.
    Citations: 2     
  26. Liu Y, Jordan JT, Bredella MA, Erdin S, Walker JA, Vangel M, Harris GJ, Plotkin SR, Cai W. Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics. Neurology. 2020 06 16; 94(24):e2521-e2531. PMID: 32345730.
    Citations: 2     Fields:    Translation:Humans
  27. Klesse LJ, Jordan JT, Radtke HB, Rosser T, Schorry E, Ullrich N, Viskochil D, Knight P, Plotkin SR, Yohay K. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Oncologist. 2020 07; 25(7):e1109-e1116. PMID: 32272491.
    Citations: 5     Fields:    Translation:Humans
  28. Lester EG, Macklin EA, Plotkin S, Vranceanu AM. Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program. J Neurooncol. 2020 Apr; 147(2):451-457. PMID: 32078086.
    Citations: 1     Fields:    Translation:Humans
  29. Lester E, DiStefano S, Mace R, Macklin E, Plotkin S, Vranceanu AM. Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial. Gen Hosp Psychiatry. 2020 Jan - Feb; 62:72-78. PMID: 31841875.
    Citations: 2     Fields:    Translation:Humans
  30. Greenberg J, Carter S, Lester E, Funes CJ, Macklin EA, Plotkin S, Vranceanu AM. Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live-video randomized control trial. J Neurooncol. 2019 Dec; 145(3):561-569. PMID: 31677033.
    Citations:    Fields:    Translation:Humans
  31. Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454. PMID: 31626572.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  32. Gerstner ER, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T. Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020 01 01; 26(1):206-212. PMID: 31558474.
    Citations: 11     Fields:    Translation:Humans
  33. Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER. Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2019 Jun 14; 9(1):8721. PMID: 31197238.
    Citations:    Fields:    
  34. Funes CJ, Mace RA, Macklin EA, Plotkin SR, Jordan JT, Vranceanu AM. First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. J Neurooncol. 2019 Jul; 143(3):505-513. PMID: 31049826.
    Citations: 3     Fields:    Translation:Humans
  35. Ferner RE, Bakker A, Elgersma Y, Evans DGR, Giovannini M, Legius E, Lloyd A, Messiaen LM, Plotkin S, Reilly KM, Schindeler A, Smith MJ, Ullrich NJ, Widemann B, Sherman LS. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis. Am J Med Genet A. 2019 06; 179(6):1098-1106. PMID: 30908866.
    Citations: 1     Fields:    Translation:HumansAnimals
  36. Rauen KA, Alsaegh A, Ben-Shachar S, Berman Y, Blakeley J, Cordeiro I, Elgersma Y, Evans DG, Fisher MJ, Frayling IM, George J, Huson SM, Kerr B, Khire U, Korf B, Legius E, Messiaen L, van Minkelen R, Nampoothiri S, Ngeow J, Parada LF, Phadke S, Pillai A, Plotkin SR, Puri R, Raji A, Ramesh V, Ratner N, Shankar SP, Sharda S, Tambe A, Vikkula M, Widemann BC, Wolkenstein P, Upadhyaya M. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics. Am J Med Genet A. 2019 06; 179(6):1091-1097. PMID: 30908877.
    Citations:    Fields:    Translation:HumansCells
  37. Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, Ng MR, Chen JW, Zhang N, Zhao Y, Gao X, Fujita T, Roberge S, Huang P, Jain RK, Plotkin SR, Stankovic KM, Xu L. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nat Protoc. 2019 02; 14(2):541-555. PMID: 30617350.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  38. Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2018 11 20; 8(1):17062. PMID: 30459364.
    Citations: 5     Fields:    Translation:Humans
  39. Vranceanu AM, Zale EL, Funes CJ, Macklin EA, McCurley J, Park ER, Jordan JT, Lin A, Plotkin SR. Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. JMIR Res Protoc. 2018 Oct 23; 7(10):e11008. PMID: 30355560.
    Citations: 6     
  40. Merker VL, Dai A, Radtke HB, Knight P, Jordan JT, Plotkin SR. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv Res. 2018 Aug 29; 18(1):668. PMID: 30157837.
    Citations: 3     Fields:    Translation:Humans
  41. Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 08 02; 20(9):1185-1196. PMID: 29982664.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  42. Jordan JT, Plotkin SR. Benign Intracranial Tumors. Neurol Clin. 2018 08; 36(3):501-516. PMID: 30072068.
    Citations: 2     Fields:    Translation:Humans
  43. Verma SK, Riccardi VM, Plotkin SR, Weinberg H, Anderson RR, Blakeley JO, Jarnagin K, Lee J. Considerations for development of therapies for cutaneous neurofibroma. Neurology. 2018 07 10; 91(2 Suppl 1):S21-S30. PMID: 29987132.
    Citations: 6     Fields:    Translation:Humans
  44. Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, Miller DC, Huson S, Peltonen J, Rosenberg A, Carroll SL, Verma SK, Mautner V, Upadhyaya M, Stemmer-Rachamimov A. Cutaneous neurofibromas: Current clinical and pathologic issues. Neurology. 2018 07 10; 91(2 Suppl 1):S5-S13. PMID: 29987130.
    Citations: 16     Fields:    Translation:Humans
  45. Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13(6):e0197350. PMID: 29897904.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  46. Huang V, Bergner AL, Halpin C, Merker VL, Sheridan MR, Widemann BC, Blakeley JO, Plotkin SR. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. Otol Neurotol. 2018 06; 39(5):632-638. PMID: 29649040.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  47. Plotkin SR, Wick A. Neurofibromatosis and Schwannomatosis. Semin Neurol. 2018 02; 38(1):73-85. PMID: 29548054.
    Citations: 12     Fields:    Translation:Humans
  48. Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, Zhao F, Zhao Y, Zhang Y, Zhang J, Fujita T, Stemmer-Rachamimov A, Ferraro GB, Liu H, Muzikansky A, Plotkin SR, Stankovic KM, Jain RK, Xu L. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A. 2018 02 27; 115(9):E2077-E2084. PMID: 29440379.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  49. Jordan JT, Smith MJ, Walker JA, Erdin S, Talkowski ME, Merker VL, Ramesh V, Cai W, Harris GJ, Bredella MA, Seijo M, Suuberg A, Gusella JF, Plotkin SR. Pain correlates with germline mutation in schwannomatosis. Medicine (Baltimore). 2018 Feb; 97(5):e9717. PMID: 29384852.
    Citations: 4     Fields:    Translation:Humans
  50. Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, Hsiao MC, Chen Z, Balasubramanian M, Barnett CP, Becker TA, Ben-Shachar S, Bertola DR, Blakeley JO, Burkitt-Wright EMM, Callaway A, Crenshaw M, Cunha KS, Cunningham M, D'Agostino MD, Dahan K, De Luca A, Destrée A, Dhamija R, Eoli M, Evans DGR, Galvin-Parton P, George-Abraham JK, Gripp KW, Guevara-Campos J, Hanchard NA, Hernández-Chico C, Immken L, Janssens S, Jones KJ, Keena BA, Kochhar A, Liebelt J, Martir-Negron A, Mahoney MJ, Maystadt I, McDougall C, McEntagart M, Mendelsohn N, Miller DT, Mortier G, Morton J, Pappas J, Plotkin SR, Pond D, Rosenbaum K, Rubin K, Russell L, Rutledge LS, Saletti V, Schonberg R, Schreiber A, Seidel M, Siqveland E, Stockton DW, Trevisson E, Ullrich NJ, Upadhyaya M, van Minkelen R, Verhelst H, Wallace MR, Yap YS, Zackai E, Zonana J, Zurcher V, Claes K, Martin Y, Korf BR, Legius E, Messiaen LM. Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. Am J Hum Genet. 2018 01 04; 102(1):69-87. PMID: 29290338.
    Citations: 40     Fields:    Translation:HumansCells
  51. Merker VL, McDannold S, Riklin E, Talaei-Khoei M, Sheridan MR, Jordan JT, Plotkin SR, Vranceanu AM. Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. J Neurooncol. 2018 Jan; 136(2):335-342. PMID: 29119424.
    Citations: 1     Fields:    Translation:Humans
  52. Cai W, Steinberg SM, Bredella MA, Basinsky G, Somarouthu B, Plotkin SR, Solomon J, Widemann BC, Harris GJ, Dombi E. Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods. Acad Radiol. 2018 02; 25(2):144-152. PMID: 29097016.
    Citations: 2     Fields:    Translation:Humans
  53. Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D'Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Frosch MP, Suva ML, Cahill DP, Getz G, Batchelor TT. Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. NPJ Precis Oncol. 2017; 1(1):33. PMID: 29872714.
    Citations: 6     
  54. Zhang N, Chen J, Ferraro GB, Wu L, Datta M, Jain RK, Plotkin SR, Stemmer-Rachamimov A, Xu L. Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol. 2018 01; 299(Pt B):326-333. PMID: 28911884.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  55. Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1. PMID: 29202103.
    Citations: 5     
  56. Riklin E, Talaei-Khoei M, Merker VL, Sheridan MR, Jordan JT, Plotkin SR, Vranceanu AM. First report of factors associated with satisfaction in patients with neurofibromatosis. . 2017 03; 173(3):671-677. PMID: 28211981.
    Citations: 3     Translation:Humans
  57. Talaei-Khoei M, Riklin E, Merker VL, Sheridan MR, Jordan JT, Plotkin SR, Vranceanu AM. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. J Neurooncol. 2017 01; 131(2):413-419. PMID: 27900643.
    Citations: 7     Fields:    Translation:Humans
  58. Ostrow KL, Bergner AL, Blakeley J, Evans DG, Ferner R, Friedman JM, Harris GJ, Jordan JT, Korf B, Langmead S, Leschziner G, Mautner V, Merker VL, Papi L, Plotkin SR, Slopis JM, Smith MJ, Stemmer-Rachamimov A, Yohay K, Belzberg AJ. Creation of an international registry to support discovery in schwannomatosis. . 2017 Feb; 173(2):407-413. PMID: 27759912.
    Citations: 5     Translation:HumansPHPublic Health
  59. Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016 Aug 16; 87(7 Suppl 1):S31-9. PMID: 27527647.
    Citations: 17     Fields:    Translation:Humans
  60. Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology. 2016 Aug 16; 87(7 Suppl 1):S40-8. PMID: 27527649.
    Citations: 3     Fields:    Translation:Humans
  61. Plotkin SR, Davis SD, Robertson KA, Akshintala S, Allen J, Fisher MJ, Blakeley JO, Widemann BC, Ferner RE, Marcus CL. Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1. Neurology. 2016 Aug 16; 87(7 Suppl 1):S13-20. PMID: 27527645.
    Citations: 3     Fields:    Translation:Humans
  62. Vranceanu AM, Riklin E, Merker VL, Macklin EA, Park ER, Plotkin SR. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT. Neurology. 2016 Aug 23; 87(8):806-14. PMID: 27449066.
    Citations: 19     Fields:    Translation:Humans
  63. Merker VL, Bergner AL, Vranceanu AM, Muzikansky A, Slattery W, Plotkin SR. Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History Study. Otol Neurotol. 2016 06; 37(5):574-9. PMID: 27050651.
    Citations: 4     Fields:    Translation:Humans
  64. Stevenson DA, Schill L, Schoyer L, Andresen BS, Bakker A, Bayrak-Toydemir P, Burkitt-Wright E, Chatfield K, Elefteriou F, Elgersma Y, Fisher MJ, Franz D, Gelb BD, Goriely A, Gripp KW, Hardan AY, Keppler-Noreuil KM, Kerr B, Korf B, Leoni C, McCormick F, Plotkin SR, Rauen KA, Reilly K, Roberts A, Sandler A, Siegel D, Walsh K, Widemann BC. The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway. Am J Med Genet A. 2016 08; 170(8):1959-66. PMID: 27155140.
    Citations: 6     Fields:    Translation:HumansCells
  65. Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J Clin Oncol. 2016 05 10; 34(14):1669-75. PMID: 26976425.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  66. Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol. 2016 05; 18(5):624-38. PMID: 26851632.
    Citations: 27     Fields:    Translation:Humans
  67. Naunheim MR, Plotkin SR, Franco RA, Song PC. Laryngeal Manifestations of Neurofibromatosis. Otolaryngol Head Neck Surg. 2016 Mar; 154(3):494-7. PMID: 26786267.
    Citations:    Fields:    Translation:Humans
  68. Terry AR, Jordan JT, Schwamm L, Plotkin SR. Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1: Population-Based Approach. Stroke. 2016 Jan; 47(1):60-5. PMID: 26645253.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  69. Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR. Glioblastoma care in the elderly. Cancer. 2016 Jan 15; 122(2):189-97. PMID: 26618888.
    Citations: 20     Fields:    Translation:Humans
  70. Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc Natl Acad Sci U S A. 2015 Nov 24; 112(47):14676-81. PMID: 26554010.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  71. Farschtschi S, Merker VL, Wolf D, Schuhmann M, Blakeley J, Plotkin SR, Hagel C, Mautner VF. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand. 2016 Jun; 133(6):475-80. PMID: 26369495.
    Citations: 6     Fields:    Translation:Humans
  72. Beauchamp RL, James MF, DeSouza PA, Wagh V, Zhao WN, Jordan JT, Stemmer-Rachamimov A, Plotkin SR, Gusella JF, Haggarty SJ, Ramesh V. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget. 2015 Jul 10; 6(19):16981-97. PMID: 26219339.
    Citations: 20     Fields:    Translation:HumansCells
  73. Stivaros SM, Stemmer-Rachamimov AO, Alston R, Plotkin SR, Nadol JB, Quesnel A, O'Malley J, Whitfield GA, McCabe MG, Freeman SR, Lloyd SK, Wright NB, Kilday JP, Kamaly-Asl ID, Mills SJ, Rutherford SA, King AT, Evans DG. Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. J Med Genet. 2015 Aug; 52(8):557-62. PMID: 26104281.
    Citations: 12     Fields:    Translation:Humans
  74. Korf B, Ahmadian R, Allanson J, Aoki Y, Bakker A, Wright EB, Denger B, Elgersma Y, Gelb BD, Gripp KW, Kerr B, Kontaridis M, Lazaro C, Linardic C, Lozano R, MacRae CA, Messiaen L, Mulero-Navarro S, Neel B, Plotkin S, Rauen KA, Roberts A, Silva AJ, Sittampalam SG, Zhang C, Schoyer L. The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach. . 2015 Aug; 167A(8):1741-6. PMID: 25900621.
    Citations: 4     Translation:HumansCells
  75. Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget. 2015 Feb 28; 6(6):4527-36. PMID: 25784657.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  76. Terry AR, Merker VL, Barker FG, Leffert L, Bateman BT, Souter I, Plotkin SR. Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system. Am J Obstet Gynecol. 2015 Jul; 213(1):108-109. PMID: 25687565.
    Citations: 1     Fields:    Translation:Humans
  77. Vranceanu AM, Merker VL, Park ER, Plotkin SR. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol. 2015 Apr; 122(2):219-28. PMID: 25663248.
    Citations: 9     Fields:    Translation:Humans
  78. Park ER, Smith KB, Merker VL, Muzikansky A, Vranceanu AM, Wang DL, Plotkin SR. Examining perceived cancer risk among patients with neurofibromatosis type 1. J Neurooncol. 2015 Mar; 122(1):127-33. PMID: 25559686.
    Citations: 1     Fields:    Translation:Humans
  79. Merker VL, Murphy TP, Hughes JB, Muzikansky A, Hughes MR, Souter I, Plotkin SR. Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1. Fertil Steril. 2015 Mar; 103(3):761-8.e1. PMID: 25557241.
    Citations: 2     Fields:    Translation:Humans
  80. Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6. PMID: 25527270.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  81. Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC. Update from the 2013 International Neurofibromatosis Conference. . 2014 Dec; 164A(12):2969-78. PMID: 25255738.
    Citations: 6     Translation:HumansAnimals
  82. Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21. PMID: 25100872.
    Citations: 65     Fields:    Translation:HumansCTClinical Trials
  83. Vranceanu AM, Merker VL, Plotkin SR, Park ER. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol. 2014 Oct; 120(1):103-9. PMID: 25022450.
    Citations: 18     Fields:    Translation:Humans
  84. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12. PMID: 25165209.
    Citations:    
  85. Jordan JT, Plotkin S, Dietrich J. Magnetic resonance imaging observations in primary central nervous system lymphoma. JAMA Neurol. 2014 Jul 01; 71(7):918-9. PMID: 24861724.
    Citations: 2     Fields:    Translation:Humans
  86. Jordan JT, Yang HS, Narendra D, Plotkin SR. Teaching NeuroImages: brain mass with hilar adenopathy: the importance of histologic diagnosis. Neurology. 2014 May 06; 82(18):e161-2. PMID: 24799521.
    Citations:    Fields:    Translation:Humans
  87. Urban T, Lim R, Merker VL, Muzikansky A, Harris GJ, Kassarjian A, Bredella MA, Plotkin SR. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion. Clin Nucl Med. 2014 May; 39(5):e301-7. PMID: 24152623.
    Citations: 5     Fields:    Translation:Humans
  88. Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol. 2014 Jun; 73(6):1197-204. PMID: 24710627.
    Citations: 18     Fields:    Translation:Humans
  89. Plotkin SR. Chemoprevention for neurofibromatosis 2: just over the horizon? Neuro Oncol. 2014 Apr; 16(4):471-2. PMID: 24637549.
    Citations:    Fields:    Translation:HumansAnimals
  90. Pier DB, Nunes FP, Plotkin SR, Stemmer-Rachamimov AO, Kim JC, Shih HA, Brastianos P, Lin AE. Turner syndrome and meningioma: support for a possible increased risk of neoplasia in Turner syndrome. Eur J Med Genet. 2014 May-Jun; 57(6):269-74. PMID: 24675142.
    Citations: 2     Fields:    Translation:Humans
  91. Merker VL, Bredella MA, Cai W, Kassarjian A, Harris GJ, Muzikansky A, Nguyen R, Mautner VF, Plotkin SR. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. . 2014 Jun; 164A(6):1431-7. PMID: 24664633.
    Citations: 16     Translation:Humans
  92. Sengupta S, Benkers T, Blitstein M, Palmer E, Plotkin SR, Abramson JS. Posterior reversible encephalopathy syndrome (PRES) complicating newly-diagnosed diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):e111-3. PMID: 24581553.
    Citations: 1     Fields:    Translation:Humans
  93. Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. . 2014 Mar; 164A(3):563-78. PMID: 24443315.
    Citations: 8     Translation:Humans
  94. Plotkin SR, Merker VL, Muzikansky A, Barker FG, Slattery W. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol. 2014 Jan; 35(1):e50-6. PMID: 24335938.
    Citations: 18     Fields:    Translation:Humans
  95. Widemann BC, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Plotkin SR. Conclusions and future directions for the REiNS International Collaboration. Neurology. 2013 Nov 19; 81(21 Suppl 1):S41-4. PMID: 24249805.
    Citations: 5     Fields:    Translation:Humans
  96. Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Widemann BC. Achieving consensus for clinical trials: the REiNS International Collaboration. Neurology. 2013 Nov 19; 81(21 Suppl 1):S1-5. PMID: 24249801.
    Citations: 16     Fields:    Translation:Humans
  97. Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, Fisher MJ, Goutagny S, Harris GJ, Jaramillo D, Karajannis MA, Korf BR, Mautner V, Plotkin SR, Poussaint TY, Robertson K, Shih CS, Widemann BC. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S33-40. PMID: 24249804.
    Citations: 44     Fields:    Translation:Humans
  98. Plotkin SR, Ardern-Holmes SL, Barker FG, Blakeley JO, Evans DG, Ferner RE, Hadlock TA, Halpin C. Hearing and facial function outcomes for neurofibromatosis 2 clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S25-32. PMID: 24249803.
    Citations: 10     Fields:    Translation:Humans
  99. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64. PMID: 24190997.
    Citations: 154     Fields:    Translation:HumansCTClinical Trials
  100. Fayad LM, Blakeley J, Plotkin S, Widemann B, Jacobs MA. Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis. ISRN Radiol. 2013; 2013:627932. PMID: 24967287.
    Citations: 9     
  101. Smith KB, Wang DL, Plotkin SR, Park ER. Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-consciousness. Psychooncology. 2013 Dec; 22(12):2711-9. PMID: 23873824.
    Citations: 5     Fields:    Translation:Humans
  102. Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87. PMID: 23828240.
    Citations: 83     Fields:    Translation:HumansCells
  103. Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013 Sep; 114(3):257-62. PMID: 23817811.
    Citations: 19     Fields:    Translation:Humans
  104. Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5. PMID: 23553268.
    Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
  105. Terry AR, Barker FG, Leffert L, Bateman BT, Souter I, Plotkin SR. Neurofibromatosis type 1 and pregnancy complications: a population-based study. Am J Obstet Gynecol. 2013 Jul; 209(1):46.e1-8. PMID: 23535241.
    Citations: 10     Fields:    Translation:Humans
  106. Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, Barker FG, Stemmer-Rachamimov A, Plotkin SR. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One. 2013; 8(3):e59941. PMID: 23555840.
    Citations: 18     Fields:    Translation:Humans
  107. Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M. Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. . 2013 Mar; 161A(3):405-16. PMID: 23401320.
    Citations: 53     Translation:HumansAnimals
  108. Smith MJ, Esparza S, Merker VL, Muzikansky A, Bredella MA, Harris GJ, Kassarjian A, Cai W, Walker JA, Mautner VF, Plotkin SR. Plasma S100ß is not a useful biomarker for tumor burden in neurofibromatosis. Clin Biochem. 2013 May; 46(7-8):698-700. PMID: 23261835.
    Citations: 1     Fields:    Translation:Humans
  109. van Eeghen AM, Pulsifer MB, Merker VL, Neumeyer AM, van Eeghen EE, Thibert RL, Cole AJ, Leigh FA, Plotkin SR, Thiele EA. Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol. 2013 Feb; 55(2):146-53. PMID: 23205844.
    Citations: 48     Fields:    Translation:Humans
  110. Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg. 2013 Jan; 118(1):142-8. PMID: 23101443.
    Citations: 14     Fields:    Translation:Humans
  111. Wirth LJ, Plotkin SR, Emerick KS, Cunnane ME, Faquin WC. Case records of the Massachusetts General Hospital. Case 29-2012. A 49-year-old man with pain and cranial-nerve palsies after treatment of oral cancer. N Engl J Med. 2012 Sep 20; 367(12):1136-47. PMID: 22992078.
    Citations: 3     Fields:    Translation:Humans
  112. Smith MJ, Walker JA, Shen Y, Stemmer-Rachamimov A, Gusella JF, Plotkin SR. Expression of SMARCB1 (INI1) mutations in familial schwannomatosis. Hum Mol Genet. 2012 Dec 15; 21(24):5239-45. PMID: 22949514.
    Citations: 12     Fields:    Translation:HumansCells
  113. Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012; 17(10):1317-22. PMID: 22927469.
    Citations: 49     Fields:    Translation:Humans
  114. Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, Plotkin SR. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med. 2012 Dec; 14(12):977-82. PMID: 22878510.
    Citations: 22     Fields:    Translation:Humans
  115. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012 Aug; 33(6):1046-52. PMID: 22805104.
    Citations: 68     Fields:    Translation:Humans
  116. Vakharia KT, Henstrom D, Plotkin SR, Cheney M, Hadlock TA. Facial reanimation of patients with neurofibromatosis type 2. Neurosurgery. 2012 Jun; 70(2 Suppl Operative):237-43. PMID: 21968382.
    Citations: 4     Fields:    Translation:Humans
  117. Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One. 2012; 7(4):e35711. PMID: 22558206.
    Citations: 45     Fields:    Translation:Humans
  118. Terry AR, Barker FG, Leffert L, Bateman BT, Souter I, Plotkin SR. Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study. Neuro Oncol. 2012 Jun; 14(6):768-76. PMID: 22513749.
    Citations: 8     Fields:    Translation:Humans
  119. Terry AR, Plotkin SR. Chemotherapy: present and future. Otolaryngol Clin North Am. 2012 Apr; 45(2):471-86, x. PMID: 22483828.
    Citations:    Fields:    Translation:Humans
  120. Hagel C, Stemmer-Rachamimov AO, Bornemann A, Schuhmann M, Nagel C, Huson S, Evans DG, Plotkin S, Matthies C, Kluwe L, Mautner VF. Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. Neuropathology. 2012 Dec; 32(6):611-6. PMID: 22394059.
    Citations: 8     Fields:    Translation:Humans
  121. Uhlmann EJ, Plotkin SR. Neurofibromatoses. Adv Exp Med Biol. 2012; 724:266-77. PMID: 22411249.
    Citations: 10     Fields:    Translation:Humans
  122. Jaremko JL, MacMahon PJ, Torriani M, Merker VL, Mautner VF, Plotkin SR, Bredella MA. Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis. Skeletal Radiol. 2012 Aug; 41(8):917-23. PMID: 22146869.
    Citations: 10     Fields:    Translation:Humans
  123. Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. . 2012 Jan; 158A(1):24-41. PMID: 22140088.
    Citations: 33     Translation:Humans
  124. Norden AD, Hammond S, Drappatz J, Phuphanich S, Reardon DA, Wong E, Plotkin SR, Lesser GJ, Raizer JJ, Batchelor T, Quant EC, Beroukhim R, Kaley TJ, Muzikansky A, Ciampa AS, Doherty LM, Smith KH, Gerard M, Sceppa C, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040. PMID: 28023794.
    Citations:    
  125. Plotkin SR, Jennings D, Mouridsen K, Emblem KE, Sorensen AG. Vascular hemodynamic profiles of vestibular schwannomas and glioblastoma using MRI. J Clin Oncol. 2011 May 20; 29(15_suppl):2047. PMID: 28023808.
    Citations:    
  126. Plotkin SR, O'Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J Neurosurg Spine. 2011 Apr; 14(4):543-7. PMID: 21294614.
    Citations: 24     Fields:    Translation:Humans
  127. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28. PMID: 21199795.
    Citations: 87     Fields:    Translation:Humans
  128. Jeyaretna DS, Curry WT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol. 2011 Mar 01; 29(7):e159-62. PMID: 21149667.
    Citations: 29     Fields:    Translation:HumansPHPublic Health
  129. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32. PMID: 20821342.
    Citations: 40     Fields:    Translation:HumansCTClinical Trials
  130. Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010 Sep; 31(7):1135-43. PMID: 20736812.
    Citations: 31     Fields:    Translation:Humans
  131. Miriam J. Smith and Scott R. Plotkin. Neurofibromatosis and Schwannomatosis. The MGH Guide to Clinical Cancer Genetics (eds., DC Chung and DA Haber). 2010; in press.
  132. Fabio P. Nunes, Scott R. Plotkin, Anat Stemmer-Rachamimov. Histopathology and Molecular Pathogenesis of Schwannomas. Principles and Practices of Neuro-Oncology: A Multidisciplinary Approach (Mehta, Chang, Vogelbaum, Guha, et al., Editors). 2010; in press.
  133. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23. PMID: 20458050.
    Citations: 219     Fields:    Translation:HumansCTClinical Trials
  134. Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 2010 May 01; 70(9):3483-93. PMID: 20406973.
    Citations: 41     Fields:    Translation:HumansAnimalsCells
  135. R Cavaliere, B O’Neill, S Plotkin, G van Imhoff, E Neuwelt, K Jahnke, L Abrey, T Batchelor, G Illerhaus, S Horning, G Petroni, B Lopes, and D Schiff. Primary CNS Post-Transplant Lymphoproliferative Disorder: The International PCNSL Collaborative Group Experience. Cancer. 2009; in press.
  136. El-Jawahri A, Podgurski LM, Eichler AF, Plotkin SR, Temel JS, Mitchell SL, Chang Y, Barry MJ, Volandes AE. Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol. 2010 Jan 10; 28(2):305-10. PMID: 19949010.
    Citations: 78     Fields:    Translation:Humans
  137. Shen Y, Nunes F, Stemmer-Rachamimov A, James M, Mohapatra G, Plotkin S, Betensky RA, Engler DA, Roy J, Ramesh V, Gusella JF. Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics. 2009 Jul 09; 2:42. PMID: 19589153.
    Citations: 14     Fields:    
  138. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009 Jul 23; 361(4):358-67. PMID: 19587327.
    Citations: 145     Fields:    Translation:Humans
  139. Batchelor T, Eichler AF, Plotkin SR, Drappatz J, Wen P, Sorensen AG, Gerstner E. Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2035. PMID: 27964624.
    Citations:    
  140. Plotkin SR, Singh M, Cai W, O'Donnell C, Esparza S, Smith MJ, Harris GJ, Muzikansky A, Bredella MA, Kassarjian A. Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor suppressor syndromes. J Clin Oncol. 2009 May 20; 27(15_suppl):2074. PMID: 27964382.
    Citations:    
  141. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009 Aug; 29(15):4250-61. PMID: 19451225.
    Citations: 110     Fields:    Translation:HumansAnimalsCells
  142. Plotkin SR, Halpin C, Blakeley JO, Slattery WH, Welling DB, Chang SM, Loeffler JS, Harris GJ, Sorensen AG, McKenna MJ, Barker FG. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol. 2009 May; 93(1):61-77. PMID: 19430883.
    Citations: 23     Fields:    Translation:Humans
  143. Smith MJ, Boyd CD, MacCollin MM, Plotkin SR. Identity analysis of schwannomatosis kindreds with recurrent constitutional SMARCB1 (INI1) alterations. Clin Genet. 2009 May; 75(5):501-2. PMID: 19320657.
    Citations: 3     Fields:    Translation:Humans
  144. Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, and Plotkin SR. Determination of Tumor Burden in NF1, NF2, and Schwannomatosis on Whole Body MR Images. Radiology. 2009; 250(3):665-73.
  145. Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009 Mar; 250(3):665-73. PMID: 19244040.
    Citations: 38     Fields:    Translation:Humans
  146. Lu-Emerson C, Plotkin SR. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis. 2009; 6(3):E81-6. PMID: 19898272.
    Citations: 21     Fields:    Translation:Humans
  147. Lu-Emerson C, Plotkin SR. The Neurofibromatoses. Part 1: NF1. Rev Neurol Dis. 2009; 6(2):E47-53. PMID: 19587630.
    Citations: 18     Fields:    Translation:Humans
  148. McQueen M, MacCollin M, Gusella J, Plotkin SR. Patient and physician attitudes regarding clinical trials in neurofibromatosis 1. J Neurosci Nurs. 2008 Dec; 40(6):341-5. PMID: 19170300.
    Citations: 2     Fields:    Translation:Humans
  149. David Reardon, Karen Fink, Tom Mikkelsen, Timothy Cloughesy, Alison O'Neill, Scott Plotkin, Michael Glantz, Paula Ravin, Jeffrey Raizer, Keith Rich, David Schiff, William Shapiro, Susan Burdette-Radoux, Edward Dropcho, Sabine Wittemer, Johannes Nippgen, Martin Picard, Louis Nabors. Activity of Cilengitide, an Integrin-Targeting RGD Peptide, Among Adults with Recurrent Glioblastoma Multiforme: Results of a Randomized Phase 2 Study. J Clin Oncol. 2008; 26(34):5610-5617.
  150. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008 Dec 01; 26(34):5610-7. PMID: 18981465.
    Citations: 182     Fields:    Translation:HumansCTClinical Trials
  151. S.R. Plotkin. Phakomatoses: Neurofibromatosis 2. In Larry R. Squire, Editor-in-Chief, The New Encyclopedia of Neuroscience. 2008.
  152. Boyd C, Smith MJ, Kluwe L, Balogh A, Maccollin M, Plotkin SR. Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet. 2008 Oct; 74(4):358-66. PMID: 18647326.
    Citations: 52     Fields:    Translation:HumansCells
  153. Eichler AF, Plotkin SR. Brain metastases. Curr Treat Options Neurol. 2008 Jul; 10(4):308-14. PMID: 18579017.
    Citations: 6     
  154. Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol. 2008 Aug; 5(8):487-91. PMID: 18560388.
    Citations: 21     Fields:    Translation:Humans
  155. Harris GJ, Plotkin SR, Maccollin M, Bhat S, Urban T, Lev MH, Slattery WH. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery. 2008 Jun; 62(6):1314-9; discussion 1319-20. PMID: 18824998.
    Citations: 32     Fields:    Translation:Humans
  156. di Tomaso E, Frosch MP, Auluck PK, Cahill D, Duda DG, Plotkin SR, Loeffler JS, Sorensen AG, Batchelor TT, Jain RK. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment. J Clin Oncol. 2008 May 20; 26(15_suppl):2009. PMID: 27948447.
    Citations:    
  157. Plotkin SR, Halpin CF, McKenna MJ, Batchelor TT, Loeffler JS, Barker FG. Treatment of progressive neurofibromatosis type 2-related vestibular schwannoma with erlotinib. J Clin Oncol. 2008 May 20; 26(15_suppl):2045. PMID: 27948119.
    Citations:    
  158. Scott Randall Plotkin. Neurofibromatosis type 2 and related disorders. Ruggieri M, Pascual-Castroviejo I, and DiRocco C, editors. Neurocutaneous Disorders: Phakomatoses and Hamartoneoplastic Sydnromes. 2008; 153-180.
  159. Wendell LC, Freeman SH, Plotkin SR, Sims JR. Clinical reasoning: a case of multiple intracerebral hemorrhages. Neurology. 2007 Dec 04; 69(23):E30-4. PMID: 18056573.
    Citations: 2     Fields:    Translation:Humans
  160. Farrell CJ, Plotkin SR. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol Clin. 2007 Nov; 25(4):925-46, viii. PMID: 17964021.
    Citations: 28     Fields:    Translation:HumansCells
  161. Chu-Shore C and Plotkin SR. The Phakomatoses. Rosenberg RN, DiMauro S, Paulson H, Ptacek L, Nestler E, editors. The molecular and genetic basis of neurological and psychiatric disease. 2007.
  162. Bredella MA, Torriani M, Hornicek F, Ouellette HA, Plamer WE, Williams Z, Fischman AJ, Plotkin SR. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol. 2007 Oct; 189(4):928-35. PMID: 17885067.
    Citations: 30     Fields:    Translation:Humans
  163. James MF, Lelke JM, Maccollin M, Plotkin SR, Stemmer-Rachamimov AO, Ramesh V, Gusella JF. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis. 2008 Feb; 29(2):278-92. PMID: 17962031.
    Citations: 23     Fields:    Translation:HumansCells
  164. Alcalay RN, Shulman JM, Plotkin SR. Ramsay Hunt syndrome in a patient with metastatic lung cancer to brain. J Neurooncol. 2008 Jan; 86(1):55-6. PMID: 17634859.
    Citations:    Fields:    Translation:Humans
  165. Greer DM, Schaefer PW, Plotkin SR, Hasserjian RP, Steere AC. Case records of the Massachusetts General Hospital. Case 11-2007. A 59-year-old man with neck pain, weakness in the arms, and cranial-nerve palsies. N Engl J Med. 2007 Apr 12; 356(15):1561-70. PMID: 17429088.
    Citations: 2     Fields:    Translation:HumansCells
  166. Plotkin SR and Grier JT. Increased intracranial pressure and extradural compression syndromes. In: Baehring JM and Piepmeier JM, editors. Brain tumors: practical guide to diagnosis and treatment. 2007; 89:427-446.
  167. Scott Plotkin, M.D., Ph.D. About Neurofibromatosis 2. 2007.
  168. Fitzsimmons AL and Plotkin SR. Metastatic brain tumors. In: Longo D, Chabner B, and Lynch T, editors. Harrison's Handbook of Oncology. 2007.
  169. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95. PMID: 17222792.
    Citations: 692     Fields:    Translation:HumansCellsCTClinical Trials
  170. Plotkin SR. Update on primary central nervous system lymphoma. Curr Opin Neurol. 2005 Dec; 18(6):645-53. PMID: 16280675.
    Citations: 1     Fields:    Translation:Humans
  171. Mrugala MM, Batchelor TT, Plotkin SR. Peripheral and cranial nerve sheath tumors. Curr Opin Neurol. 2005 Oct; 18(5):604-10. PMID: 16155448.
    Citations: 27     Fields:    Translation:Humans
  172. MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES. Diagnostic criteria for schwannomatosis. Neurology. 2005 Jun 14; 64(11):1838-45. PMID: 15955931.
    Citations: 85     Fields:    Translation:Humans
  173. Plotkin SR, Dorfman MV, Loeffler JS. Facial numbness in a man with inguinal and retroperitoneal masses. Nat Clin Pract Oncol. 2005 Jan; 2(1):54-8; quiz 1 p following 58. PMID: 16264857.
    Citations:    Fields:    Translation:Humans
  174. Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004 Sep 01; 10(17):5643-6. PMID: 15355887.
    Citations: 53     Fields:    Translation:Humans
  175. Plotkin SR, Wen PY. Neurologic complications of cancer therapy. In: Wen PY, Glanz MJ, editors. Neurologic Clinics: Neurologic Complications of Cancer. 2003; 21(1):279-318.
  176. Plotkin SR, Wen PY. Neurologic complications of cancer therapy. Neurol Clin. 2003 Feb; 21(1):279-318, x. PMID: 12690653.
    Citations: 17     Fields:    Translation:Humans
  177. Plotkin SR, Batchelor TT. Primary nervous system lymphoma. Curr Treat Options Oncol. 2002 Dec; 3(6):525-35. PMID: